LOCORTEN ® is a drug based on Neomycin sulphate and Flumetasone pivalate
THERAPEUTIC GROUP: Corticosteroids, associations with antiseptics
Indications LOCORTEN ® Neomycin + Flumetasone
LOCORTEN ® is indicated in the treatment of inflammatory skin conditions sensitive to treatment with corticosteroids.
Mechanism of action LOCORTEN ® Neomycin + Flumethasone
Neomycin and Flumetasone, active ingredients of LOCORTEN ®, are elements with different and complementary therapeutic activities effective in the treatment of inflammatory skin lesions even when highly exposed to the risk of bacterial infections. In fact, while Flumetasone, like other synthetic corticosteroids, is able to control the inflammatory evolution of the lesion, reducing the production of inflammatory mediators and the recall and activation of cellular elements involved in the genesis of symptoms, Neomycin, an antibiotic belonging to the Aminoglycoside family, it is able to inhibit the protein synthesis of Gram positive and Gram negative bacteria, inducing the death of the microorganism. This complete pattern of activity therefore allows to control the symptoms complained of by the patient, while also providing active protection against possible bacterial superinfections.
Studies carried out and clinical efficacy
LOCORTON AND CORTICOSTEROID DERMATOSIS J Int Med Res. 1987 Sep-Oct; 15: 255-63.
Combination dermatological products: a comparison of betamethasone dipropionate / clotrimazole / gentamicin sulphate and flumethasone pivalate / clioquinol creams.
Hojyo T.
Study that demonstrates the excellent therapeutic result obtained from the use of LOCORTEN in the treatment of erythema and pruritus in patients with topical corticosteroid dermatitis, with a very rapid improvement in symptoms
NEW METHODS OF DELIVERY Int J Pharm. 2009 Mar 31; 370 (1-2): 181-6. doi: 10.1016 / j.ijpharm.2008.11.014. Epub 2008 Nov 27.
Lecithin based nanoemulsions: A comparative study of the influence of non-ionic surfactants and the cationic phytosphingosine on physicochemical behavior and skin permeation.
Hoeller S, Sperger A, Valenta C.
Yet another pharmacokinetic study that evaluates the efficacy of lecithin-based nano emulsions in improving the release of the drug topically, ensuring greater therapeutic success.
LOCORTEN IN DENTISTRY Drugs Exp Clin Res. 1985; 11: 523-6.
Flumethasone pivalate (Locorten) in the treatment of oral diseases.
Scaglione F, Falchi M, Bichisao E, Fraschini F.
Dated study that demonstrates the efficacy of Locorten in the treatment of oral cavity pathologies such as periodontitis, stomatitis and post-prosthesis abscesses, guaranteeing a rapid remission of symptoms.
Method of use and dosage
LOCORTEN ® Cream for cutaneous use and ointment with 0.02% of Flumetasone pivalate and 0.5% of Neomycin sulphate. The doctor should define the methods of application, the choice of the type of pharmaceutical format and the dosages and timing based on the general health conditions of the patient and the severity of his clinical picture. appropriate amount of drug directly on the treated region 4-6 times a day in the initial phases of therapy to halve it in the phases of remission.
LOCORTEN ® Neomycin + Flumetasone warnings
The use of LOCORTEN ® should be preceded by a careful medical examination aimed at clarifying the origin of the lesion and the possible prescribing appropriateness. limiting the incidence of potential side effects such as washing hands after each application, avoiding the application of the drug on very large areas or in contact with eyes and mucous membranes, avoiding the use of occlusive bandages without proper medical prescription, consult your doctor immediately following the occurrence of side effects and keep the drug out of the reach of children.
PREGNANCY AND BREASTFEEDING
Contraindications to the use of LOCORTEN ® generally also extend to pregnancy and the subsequent period of breastfeeding, given the potential side effects of systemic corticosteroids for the health of the fetus and infant.
Interactions
There are currently no known drug interactions worthy of clinical note, although it should be remembered that the simultaneous intake of drugs inhibiting the cytochromial system can cause an increase in blood concentrations of the absorbed corticosteroid.
Contraindications LOCORTEN ® Neomycin + Flumetasone
The use of LOCORTEN ® is contraindicated in patients hypersensitive to the active substance or to one of its excipients, in patients with inadequately treated viral, bacterial and fungal infections and atopic dermatitis.
Undesirable Effects - Side Effects
Therapy with LOCORTEN ®, especially when prolonged for a long time, could determine the onset of local and fortunately transient side effects such as burning, irritation, itching, dry skin, hypopigmentation and hypertrichosis. The clinically relevant side effects are decidedly rarer. such as to require an immediate suspension of the therapy in progress.
Note
LOCORTEN ® is a drug subject to mandatory medical prescription.
The information on LOCORTEN ® Neomycin + Flumetasone published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.
